FDA Approves Supplemental NDA for OXAYDO by ZYLA
The FDA has approved a supplemental NDA for OXAYDO, an oxycodone hydrochloride product.
Asset / Drug
Drug and asset intelligence for OXAYDO with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.